Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions
Repeated cycles of rozanolixizumab resulted in consistent, clinically meaningful improvements across cycles in MG-specific outcomes with an acceptable safety profile, supporting rozanolixizumab as a treatment option for adults with AChR and MuSK autoantibody-positive gMG.
Authors
- John Vissing (ORCID: https://orcid.org/0000-0001-6144-8544)
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Artur Drużdż (ORCID: https://orcid.org/0009-0008-6502-2952)
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- Maryam Gayfieva
- Marion Boehnlein
- Sabrina Sacconi (ORCID: https://orcid.org/0000-0002-0246-1455)
- Franz Woltering
- Bernhard Greve
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Julian Großkreutz (ORCID: https://orcid.org/0000-0001-9525-1424)
- Thaïs Tarancón
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
Institutions
- University of Copenhagen (DK)
- University Health Network (CA)
- Université Côte d'Azur (FR)
- University of California, Irvine (US)
- University of South Florida (US)
- Rigshospitalet (DK)
- Centre Hospitalier Universitaire de Nice (FR)
- National Hospital Organization Hanamaki Hospital (JP)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- UCB Pharma (Germany) (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Neuromuscular Diseases
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1177/22143602241305511
- Citations
- 8
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 11.11
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Regeneron Pharmaceuticals
- Japan Blood Products Organization
- Novo Nordisk
- Grifols
- Genentech
- Sanofi Genzyme